Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVNS
AVNS logo

AVNS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Avanos Medical Inc (AVNS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
25.030
1 Day change
0.12%
52 Week Range
25.490
Analysis Updated At
2026/06/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Avanos Medical Inc (AVNS) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. There is no proprietary buy signal today, no supportive valuation data, and the stock trend data is unavailable, which prevents a confident technical entry decision. Based on the information provided, the best call is to hold and wait for clearer evidence of trend strength, fundamentals, and sentiment improvement before committing capital.

Technical Analysis

Technical analysis is limited because the stock trend data could not be fetched. The only usable price context is that AVNS is moving with the S&P 500 at 0% change, which does not indicate outperformance or momentum. With no trend confirmation, no SwingMax buy signal, and no AI Stock Picker signal, there is no technical evidence of a favorable entry today. For a beginner and long-term investor, this does not present a clear buy setup.

Positive Catalysts

  • No clear positive event-driven catalyst was provided in the data. The main supportive point is the absence of negative market shock in the supplied snapshot, but there is no strong catalyst suggesting immediate upside.

Neutral/Negative Catalysts

  • No recent congress trading data is available. No valuation data is provided, stock trend data failed to load, and there is no AI Stock Picker or SwingMax signal. These gaps reduce confidence in a near-term buy decision. No notable politician or influential figure buy/sell activity was provided.

Financial Performance

No latest quarter financial data was provided, so revenue, earnings, margin, and growth trends cannot be assessed. The latest quarter season is not available from the supplied data, preventing a meaningful financial momentum review.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so the recent Wall Street view cannot be summarized from the available inputs. With no evidence of improving analyst sentiment, the pro/con balance remains neutral to cautious.

Wall Street analysts forecast AVNS stock price to rise
Analyst Rating
0
Wall Street analysts forecast AVNS stock price to rise
Buy
Hold
Sell
0
Current: 24.980
sliders
Low
0
Averages
0
High
0
0
Current: 24.980
sliders
Low
0
Averages
0
High
0
Barclays
NULL -> Overweight
upgrade
$9 -> $11
AI Analysis
2026-01-16
Reason
Barclays
Price Target
$9 -> $11
AI Analysis
2026-01-16
upgrade
NULL -> Overweight
Reason
Barclays raised the firm's price target on Aveanna to $11 from $9 and keeps an Overweight rating on the shares. The firm upped estimates post the company's Q4 preannouncement.
William Blair
Jared Haase
Outperform
initiated
2025-12-08
Reason
William Blair
Jared Haase
Price Target
2025-12-08
initiated
Outperform
Reason
William Blair analyst Jared Haase initiated coverage of Aveanna with an Outperform rating. Preferred payers are producing a more respectable growth algorithm, the analyst tells investors in a research note. Aveanna is positioned as an attractive smid-cap healthcare services holding, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AVNS
Unlock Now

People Also Watch